Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways.
- DOI
- 10.1016/j.trsl.2026.09.002
- Published
- 2026 Sep 6
- Container
- Translational research : the journal of laboratory and clinical medicine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.trsl.2026.09.002,
title = {Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways.},
author = {Ramadan WS and Talaat IM and Al-Azawi AM and Ibrahim N and Al-Sherief S and Salih SS and Mohamed R and Sharaf BM and Semreen MH and Hersi F and Omar HA and El-Awady R},
year = {2026},
journal = {Translational research : the journal of laboratory and clinical medicine},
doi = {10.1016/j.trsl.2026.09.002},
url = {https://doi.org/10.1016/j.trsl.2026.09.002}
}RIS
TY - JOUR TI - Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways. AU - Ramadan WS AU - Talaat IM AU - Al-Azawi AM AU - Ibrahim N AU - Al-Sherief S AU - Salih SS AU - Mohamed R AU - Sharaf BM AU - Semreen MH AU - Hersi F AU - Omar HA AU - El-Awady R PY - 2026 JO - Translational research : the journal of laboratory and clinical medicine DO - 10.1016/j.trsl.2026.09.002 UR - https://doi.org/10.1016/j.trsl.2026.09.002 ER -
APA
WS, R., IM, T., AM, A., N, I., S, A., SS, S., R, M., BM, S., MH, S., F, H., HA, O., & R, E. (2026). Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways.. Translational research : the journal of laboratory and clinical medicine. https://doi.org/10.1016/j.trsl.2026.09.002
Source records
- pubmed · retrieved 2026-09-26T02:21:15.853Z